hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation

• Conditions: Leukemia

• Registration Number: NCT03759899
• Lead Sponsor: Peking University People's Hospital

Brief Summary

hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation

Detailed Description

Establishment of Clinical Applicable Human Amniotic Epithelial Cell Products and Its Preliminary Application in Allogeneic Hematopoietic Stem Cell Transplantation

Study Timeline

• Study First Submitted: 2018-11-19
• Study First Submitted QC: 2018-11-29
• Study First Posted: 2018-11-30
• Study Start: 2020-07-01
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-30
• Last Update Posted: 2020-10-01
• Primary Completion: 2021-07
• Study Completion: 2022-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• leukemia patients with allogeneic HSCT
• KFS score >90
• after transplantation, the patient was implanted (peripheral blood neutrophil absolute value >500/ul for 3 consecutive days)
• no uncontrolled infection after transplantation
• activity II above aGVHD
• patients agreed to participate in the study

Exclusion Criteria

• patients refused to participate in the study
• patients have poor compliance
• has received hormone therapy
• patients had serious heart, lung, liver, kidney and other vital organs damage
• researchers believe that patients who are not suitable for observation study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cell counts of T cells, NK cells, B cells and monocytes	Day 7	proliferation and apoptosis of T cells, NK cells, B cells and monocytes in peripheral blood of patients

Trial Locations

Locations (1)

Peking University Institute of Hematology; 🇨🇳 Beijing, Beijing, China